Log in with your email address username.


[Correspondence] Tranexamic acid for post-partum haemorrhage in the WOMAN trial

We read with interest the WOMAN trial (May 27, p 2105).1 Tranexamic acid is an antifibrinolytic drug used to reduce haemorrhage complications in trauma and elective surgery. The WOMAN trial originally planned to enrol 15 000 women with a composite primary endpoint of death from all causes or hysterectomy within 42 days of giving birth. The trial increased the number of participants to more than 20 000 “in the hope that the trial would have enough power to detect a reduction in post-partum haemorrhage death”.